

REGN · NASDAQ · WEEK ENDED 24 JUL 2026

Weekly Investor Report

Regeneron Pharmaceuticals Inc · Healthcare · Biotechnology

LATEST CLOSE

656.0 USD

-3.1% latest week

Weekly setup

Mixed setup

The weekly trend is not active. Price is -8.1% below the Trend Line and sits at 41.9% of its 52-week range. The latest completed week returned -3.1%, after a 3.7% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 39/100 conviction, while the latest news-sentiment score is 47/100. Near-term considerations: volume confirmation is below normal; earnings are due in 0d.

Technical setup score 37/100. This score describes the weekly technical setup; the conclusion above also considers fundamentals, positioning, sentiment, and event risk.

LATEST CLOSE

656.0 USD

24 Jul 2026

1W RETURN

-3.1%

latest completed week

4W RETURN

3.7%

short-term follow-through

12W RETURN

-6.3%

quarterly tape

TREND BREADTH

55.8%

29 of 52 weeks active

VOLUME RATIO

0.8x

vs 13-week average

What is working

- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.

What could go wrong

- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.

What to watch next

- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.

This week's evidence at a glance

PRICE FOLLOW-THROUGH

-3.1%

Latest completed week; four-week move 3.7%.

INDICATOR STACK

31/41

Trend and activity pressure are weighted against the latest 12-week confirmation window.

TREND BACKDROP

Active

The trend backdrop defines the current weekly regime.

PATIENT CAPITAL

Quiet

Activity-pressure buy-signal status for institutional accumulation timing.

OPTIONS PRESSURE

Mixed

39/100 conviction; expected move 8.0%.

NEWS SENTIMENT

47/100

62 relevant articles in the latest sentiment read.

EVENT RISK

0d


Next report is scheduled for 30 Jul 2026; event risk rises as the date approaches.

01 · PRICE ACTION

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -8.1% below the Trend Line and sits at 41.9% of its 52-week range. The latest completed week returned -3.1%, after a 3.7% four-week move.

52-week price path



Blue: weekly close · Green: Trend Line · Orange: Sharemaestro Fair Value

Position in the 52-week range



Latest close sits at 41.9% of the 52-week range.

RANGE LOCATION

41.9%

Shows where the latest close sits between the 52-week low and high.

TREND DISTANCE

-8.1%

Price premium or discount versus the weekly Trend Line.

FAIR-VALUE GAP

-15.7%

Premium demand or model discount
versus Sharemaestro Fair Value.

HIGH-WATER GAP

-19.9%

Distance from the latest 52-week high.


02 · VOLUME AND DEMAND

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows weekly volume. Green marks an up week; orange marks a down week.



PARTICIPATION 0.8x Latest volume versus the 13-week average.	BASELINE 4.8M 13-week average volume.	ONE-YEAR BASE 4.5M 52-week average volume.	LATEST WEEKLY VOLUME 3.9M Most recent completed week.
--	---	--	---

Demand beneath price

Activity pressure and institutional-style signals


These indicators assess whether participation is improving beneath price. They are supporting evidence, not proof of institutional buying.



03 · MOMENTUM AND LEADERSHIP

Is performance persistent—and is the stock leading?

Performance is 3.7% over four weeks, -6.3% over 12 weeks, and 17.1% over one year. The current trend has remained active for 0 consecutive weeks.



Technical setup scorecard

Trend		31
Momentum		53
Activity Pressure		41
Relative Leadership		17
Next-Week Expectancy		50
Volume		34
Smart Money		32
Risk Control		41

04 · FUNDAMENTALS AND VALUATION

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.

FACTOR WEEK 26 Jul 2026 Latest published factor snapshot.	STATEMENTS THROUGH 31 Dec 2025 Financial reporting period used.	FIELD COVERAGE 100% Available factor fields.	MODEL CONFIDENCE 96% Snapshot confidence.
--	--	---	--

Relative factor standing		
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.		
Overall factor strength		88/100
Value		69/100
Quality		89/100
Momentum		67/100
Growth		20/100

Valuation How much investors are paying for earnings, sales, and cash flow.	Business quality Margins and the return generated on invested capital.
P/E Price divided by trailing earnings. 15.5x	GROSS MARGIN Gross profit retained from each unit of revenue. 84.5%
PRICE / SALES Market value relative to trailing revenue. 4.6x	OPERATING MARGIN Operating profit retained from revenue. 34.9%
EV / EBITDA Enterprise value relative to operating cash earnings. 11.9x	FREE-CASH-FLOW MARGIN Free cash flow generated from revenue. 39.3%
FREE-CASH-FLOW YIELD Free cash flow as a share of enterprise value. 8.6%	RETURN ON INVESTED CAPITAL Operating return generated on invested capital. 14.3%

04 · FUNDAMENTALS AND VALUATION · CONTINUED

Growth, shareholder returns, and balance-sheet strength

The second half of the fundamental read separates recent business growth from cash returned to shareholders and financial leverage.

Growth and financial strength	Shareholder return and balance sheet
Recent business growth and accounting strength.	Cash returned to owners and financial leverage.
REVENUE GROWTH5.9% Latest one-year revenue growth.	DIVIDEND YIELD0.6% Cash dividends relative to market value.
EPS GROWTH-1.7% Latest one-year earnings-per-share growth.	BUYBACK YIELD4.4% Net share repurchases relative to market value.
FREE-CASH-FLOW GROWTH20.1% Latest one-year free-cash-flow growth.	SHAREHOLDER YIELD5.0% Dividend yield plus net buyback yield.
PIOTROSKI F-SCORE5/9 Nine-point accounting-strength checklist.	NET DEBT / EBITDA-0.0x Balance-sheet debt relative to operating cash earnings.

How to read this

Quality and valuation are separate questions. A strong company can still carry a demanding valuation, so profitability, growth, balance-sheet strength, and the price paid for those characteristics should be assessed independently.

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.

05 · OWNERSHIP, OPTIONS, AND SENTIMENT

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioning

Mixed

REGN shows mixed options pressure with a 39/100 conviction score, put-call volume ratio of 0.77, expected move of 8.0%, and Sharemaestro trend signal inactive.

CONVICTION

39/100

Options signal conviction.

EXPECTED MOVE

8.0%

Nearest-chain pricing.

PUT/CALL VOLUME

0.77

Contract volume balance.

Pressure

15

Speculation

42

Volatility

88

Trend agreement

57

Insider activity

0 / 20

0 acquisitions and 20 disposals in the latest 180-day insider tape. Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.

News sentiment

47/100

Weighted news tone is neutral across 62 relevant articles.

13 positive · 33 neutral · 16 negative

Patient Capital

Quiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows. No recent buy signal

06 · CATALYSTS AND RISK

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly gains and losses frame the risk around the current setup.

NEXT EARNINGS
0d
Next report is scheduled for 30 Jul 2026; event risk rises as the date approaches.


OPTIONS EXPECTED MOVE
8.0%
Nearest-chain priced movement where available.

52-WEEK DRAWDOWN
-19.9%
Distance below the 52-week high.

13-WEEK VOLATILITY
3.8%
Standard deviation of weekly returns.

Weekly gains and losses

Each bar is one completed week. Gains rise above zero; losses fall below it. Taller bars mean a larger move.



WEEKS HIGHER
13 of 26
13 weeks finished lower.

BEST WEEK
+5.9%
Week of 6 Feb.

WORST WEEK
-8.4%
Week of 22 May.

LATEST WEEK
-3.1%
Week of 24 Jul.

Shape of recent returns

Strong gains		1
Modest gains		12
Flat weeks		-
Modest losses		11
Sharp losses		2

RECENT VOL
3.8%
13-week weekly-return volatility.

UP/DOWN SPLIT
29/23
Count of positive and negative weeks in the 52-week window.

BASE VOL
4.1%
52-week weekly-return volatility.

AVERAGE SKEW
3.3% / -3.2%
Average positive week versus average negative week.

07 · SECTOR AND PEER CONTEXT

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

Sector · US Healthcare

4-WEEK RANK	GROUP AVERAGE	TREND BREADTH
33 / 100	1.3%	51.0%
Standing within the tracked group.	Average four-week return.	Share of peers with an active trend.

Peer	Exchange	1W return	4W return	Trend
ABVX	NASDAQ	-8.0%	28.9%	Active
THC	NYSE	19.6%	23.4%	Inactive
BBIO	NASDAQ	3.2%	19.6%	Active
ONC	NASDAQ	4.4%	16.4%	Inactive
MEDP	NASDAQ	11.8%	14.1%	Inactive

Industry · US Biotechnology

4-WEEK RANK	GROUP AVERAGE	TREND BREADTH
31 / 100	0.5%	67.0%
Standing within the tracked group.	Average four-week return.	Share of peers with an active trend.

Peer	Exchange	1W return	4W return	Trend
CRNX	NASDAQ	-0.2%	128.1%	Active
ABVX	NASDAQ	-8.0%	28.9%	Active
BBIO	NASDAQ	3.2%	19.6%	Active
ERAS	NASDAQ	-0.3%	19.4%	Active
IOVA	NASDAQ	-0.2%	17.4%	Active

08 · EVIDENCE AND WEEKLY DATA

The underlying research record

Every top-level statement should be traceable to a stored market, fundamental, event, or positioning observation.

Cross-signal evidence matrix

Evidence pillar	Score / read	Summary	Detail
Weekly tape	35/100	Trend, activity pressure, participation, and risk combine to a 35/100 tape read.	
Indicator analysis	11/100	Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.	Activity pressure 0.13; No reversal markers
Factors	78/100	O'Shaughnessy factor stack blends value, quality, momentum, and confidence.	Buyback Yield rank 13
SVQF	68/100	Value and quality alignment from the Sharemaestro SVQF framework.	Composite rank 235.0 of 726
Patient Capital	Quiet	Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.	No recent buy signal
Options	49/100	REGN shows mixed options pressure with a 39/100 conviction score, put-call volume ratio of 0.77, expected move of 8.0%, and Sharemaestro trend signal inactive.	Mixed · Options-market disagreement · Expected move 8.0%
Sentiment	47/100	Weighted news tone is neutral across 62 relevant articles.	REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals, Inc. Securities Class Action - Contact The Gross Law Firm
Insiders	0 / 20	0 acquisitions and 20 disposals in the latest 180-day insider tape.	
Earnings	0d	Next report is scheduled for 30 Jul 2026; event risk rises as the date approaches.	

Current evidence clusters

PRICE FOLLOW-THROUGH -3.1% Latest completed week; four-week move 3.7%.	INDICATOR STACK 31/41 Trend and activity pressure are weighted against the latest 12-week confirmation window.	TREND BACKDROP Active The trend backdrop defines the current weekly regime.	PATIENT CAPITAL Quiet Activity-pressure buy-signal status for institutional accumulation timing.
OPTIONS PRESSURE Mixed 39/100 conviction; expected move 8.0%.	NEWS SENTIMENT 47/100 62 relevant articles in the latest sentiment read.	EVENT RISK 0d Next report is scheduled for 30 Jul 2026; event risk rises as the date approaches.	

08 · EVIDENCE AND WEEKLY DATA · CONTINUED

Recent completed weeks

The completed weekly bars behind the report provide a compact audit trail for price, trend, Fair Value, activity pressure, leadership, and volume.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
24 Jul 2026	656.0 USD	-3.1%	714.1 USD	778.4 USD	-0.69	-11.92	3.9M	Off
17 Jul 2026	676.7 USD	1.8%	718.3 USD	778.9 USD	-0.80	-10.64	3.0M	Off
10 Jul 2026	664.5 USD	1.6%	721.3 USD	779.3 USD	-0.94	-15.89	3.6M	Off
03 Jul 2026	654.3 USD	3.4%	723.8 USD	779.6 USD	-1.05	-15.84	3.8M	Off
26 Jun 2026	632.9 USD	3.8%	725.8 USD	779.8 USD	-1.13	-17.98	5.6M	Off
19 Jun 2026	609.9 USD	-0.4%	730.7 USD	780.3 USD	-1.18	-24.59	5.7M	Off
12 Jun 2026	612.1 USD	-3.7%	735.5 USD	781.4 USD	-1.17	-22.49	4.9M	Off
05 Jun 2026	635.5 USD	3.4%	738.1 USD	782.4 USD	-1.13	-17.90	5.1M	Off
29 May 2026	614.8 USD	-3.8%	738.7 USD	783.1 USD	-1.12	-24.18	6.2M	Off
22 May 2026	638.9 USD	-8.4%	739.9 USD	783.8 USD	-1.09	-19.09	7.7M	Off
15 May 2026	697.2 USD	-2.3%	737.8 USD	784.4 USD	-0.86	-11.03	4.4M	Off
08 May 2026	713.9 USD	1.9%	733.7 USD	784.7 USD	-0.84	-9.45	3.3M	Off
01 May 2026	700.4 USD	-6.7%	728.7 USD	784.9 USD	-0.79	-6.39	4.8M	On
24 Apr 2026	750.5 USD	0.1%	725.3 USD	785.2 USD	-0.74	1.51	3.8M	On

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown in the fundamentals section.

Educational market research only. Not financial, investment, trading, tax, or legal advice. Market data, indicators, summaries, and reports may be delayed, incomplete, or inaccurate. You are responsible for your own decisions and should seek independent professional advice where appropriate.

Open the live report · Open the interactive chart · Full disclaimer